DILIGENCE COVER SHEET
Open evidence snapshot →Start with the evidence currently retained.
One glance at identity, filing chronology and source layers before opening the full issuer dossier.
ISSUER DOSSIER · CIK 0001889791
ISSUER IDENTITY & SOURCE LINEAGE
12 retained public-record nodesOfficial reference points for this company.
SEC CIK0001889791
Current OTC reference$INNPF · observed 2026-09-19
Earliest retained official filingD · 2021-10-26
First monitor capture2026-07-30
This page distinguishes the earliest retained official filing from an issuer’s first public trading or initial quotation date. Missing history is not a conclusion about the issuer.
INNOCAN PHARMA Corp (INNP, INNPF)
Follow saves this issuer to your watchlist. Get alerts creates in-site notices only for official events first observed after you enable alerts.
Business context
Official filing overview: we are focused on securing FDA approval for both human and veterinary drug applications.
First captured2025-08-04
Latest filingF-1/A · 2026-04-03
Registration path0 initial filings · 6 amendments
ISSUER CHANGE LEDGER
Newly detected public-record events
Events first captured by this monitoring workflow for this CIK. Open the source and the filing brief before making any legal, diligence or transaction conclusion.
- F-1/AINNOCAN PHARMA Corp (INNP, INNPF)Official source →
- F-1/AINNOCAN PHARMA Corp (INNP, INNPF)Official source →
- F-1/AINNOCAN PHARMA Corp (INNP, INNPF)Official source →
- F-1/AINNOCAN PHARMA Corp (INNP, INNPF)Official source →
- F-1/AINNOCAN PHARMA Corp (INNP, INNPD)Official source →
- F-1/AINNOCAN PHARMA Corp (INNP, INNPF)Official source →
SHELL DILIGENCE CHAIN · PUBLIC-RECORD VIEW
Evidence chain for this issuer
Built from 6 captured SEC filing nodes, from 2025-08-04 through 2026-04-03. It shows what has been observed in the record and what still needs independent verification.
- Identity anchorCIK 0001889791 · issuer name carried from the SEC filing history
- Registration entryNo initial S-1 / F-1 is in the captured record
- Amendment trail6 amendments captured
- Effectiveness / prospectusNo EFFECT or 424B is in the captured record
- Ongoing record watchLatest captured form: F-1/A on 2026-04-03
CIK and issuer name are linked to the captured SEC filing sequence.
Not present in the currently captured SEC record. This is not a negative finding.
6 amendments captured for comparison.
Not present in the currently captured SEC record. This is not a negative finding.
Verification queue
- Confirm current legal entity, officers, directors and control from the controlling filing and corporate records.
- Review capitalization, transfer-agent information and any beneficial-ownership questions through the client’s qualified advisers.
- Compare material business, financing and risk disclosure changes in the official source documents.
Source boundary
Forms captured: F-1/A. This is an evidence map, not a safety rating, shell determination, legal opinion, valuation or transaction recommendation. Absence from a captured source is never proof that a fact does not exist.
Open Evidence Snapshot →PUBLIC-RECORD DILIGENCE
Need a documented diligence trail?
Use this issuer dossier as the starting evidence layer. A defined scope can package the official filing history, public company actions and questions for your independently retained advisers to review.
FILING SEQUENCE CONTEXT
What changed in the filing path
Relationship cues are generated from the order and form type of retained official filings. They are not a clause-by-clause document redline; verify terms in the linked source.
Latest registrationF-1/A · 2026-04-03
Latest amendmentF-1/A · 2026-04-03
EffectivenessNo EFFECT retained
- Registration pathF-1/A
Amendment form captured; no prior same-lane filing is retained in this timeline
Open official filing →
OFFERING-TERM CHANGE SIGNALS
Comparable filing terms
Machine comparison found 4 retained filing pairs with comparable term-text differences. These are extracted text windows, not a definitive legal or economic comparison. Official filings control.
- F-1/A · 2026-04-03Compared with F-1/A · 2025-12-10Open later official filing →
Offer size / shares
Earlier extract: ach Consisting of One Common Share and One Warrant to Purchase One Common Share 2,350,000 Common Shares Underlying the Warrants Innocan Pharma Corporation This is the initial public offering of 2,350,000 units, each consisting of one of our common shares, no p
Later extract: rrant to Purchase One Common Share and One Warrant to Purchase One Common Share 3,750,000 Common Shares Underlying the Warrants 3,750,000 Common Shares Underlying the Pre-Funded Warrants Innocan Pharma Corporation This is the initial public offering of 3,750,0
- F-1/A · 2025-12-10Compared with F-1/A · 2025-09-30
Offer size / shares
Earlier extract: ach Consisting of One Common Share and One Warrant to Purchase One Common Share 1,088,157 Common Shares Underlying the Warrants Innocan Pharma Corporation This is the initial public offering of 1,088,157 units, each consisting of one of our common shares, no p
Later extract: ach Consisting of One Common Share and One Warrant to Purchase One Common Share 2,350,000 Common Shares Underlying the Warrants Innocan Pharma Corporation This is the initial public offering of 2,350,000 units, each consisting of one of our common shares, no p
Open later official filing →Offering price
Earlier extract: t, each to purchase one of our common shares of Innocan Pharma Corporation. The estimated initial public offering price is $13.962, based on the last reported sale price of our common shares as of September 29, 2025 on the Canadian Securities Exchange, or CSE
Later extract: each to purchase one of our common shares of Innocan Pharma Corporation. The anticipated initial public offering price is between $5.00 and $6.00 per unit. Each warrant will have an exercise price of $6.875 per Common Share (with such exercise price equal to 1
- F-1/A · 2025-09-30Compared with F-1/A · 2025-09-05
Offer size / shares
Earlier extract: ach Consisting of One Common Share and One Warrant to Purchase One Common Share 1,538,462 Common Shares Underlying the Warrants Innocan Pharma Corporation This is the initial public offering of 1,538,462 units, each consisting of one of our common shares, no p
Later extract: ach Consisting of One Common Share and One Warrant to Purchase One Common Share 1,088,157 Common Shares Underlying the Warrants Innocan Pharma Corporation This is the initial public offering of 1,088,157 units, each consisting of one of our common shares, no p
Open later official filing →Offering price
Earlier extract: t, each to purchase one of our common shares of Innocan Pharma Corporation. The estimated initial public offering price is $9.875, based on the last reported sale price of our common shares as of September 2, 2025 on the Canadian Securities Exchange, or CSE of
Later extract: t, each to purchase one of our common shares of Innocan Pharma Corporation. The estimated initial public offering price is $13.962, based on the last reported sale price of our common shares as of September 29, 2025 on the Canadian Securities Exchange, or CSE
- F-1/A · 2025-09-05Compared with F-1/A · 2025-08-04
Offer size / shares
Earlier extract: ach Consisting of One Common Share and One Warrant to Purchase One Common Share 1,538,462 Common Shares Underlying the Warrants Innocan Pharma Corporation This is the initial public offering of units, each consisting of one of our common shares, no par value,
Later extract: ach Consisting of One Common Share and One Warrant to Purchase One Common Share 1,538,462 Common Shares Underlying the Warrants Innocan Pharma Corporation This is the initial public offering of 1,538,462 units, each consisting of one of our common shares, no p
Offering price
Earlier extract: t, each to purchase one of our common shares of Innocan Pharma Corporation. The estimated initial public offering price is $9.875, based on the last reported sale price of our common shares as of July 23, 2025 on the Canadian Securities Exchange, or CSE of $9.
Later extract: t, each to purchase one of our common shares of Innocan Pharma Corporation. The estimated initial public offering price is $9.875, based on the last reported sale price of our common shares as of September 2, 2025 on the Canadian Securities Exchange, or CSE of
Open later official filing →Underwriting arrangement
Earlier extract: and other factors, as well as negotiations between the Company and representatives of the underwriters for the offering. We are both an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and a “foreig
Later extract: and other factors, as well as negotiations between the Company and representatives of the underwriters for the offering. This prospectus gives effect to a 65-for-1 reverse share split of our issued and outstanding common shares, or the Reverse Split, which was
PROJECT-FILE DOWNLOAD
Save a dated issuer evidence record.
When this company needs to move from a live review into a client, counsel, broker-dealer or internal file, generate the current source-linked Evidence Snapshot.
Official filing chronology · change cues · printable HTML · CSV source indexCONTINUE THE PUBLIC-RECORD REVIEW
Research routes for this issuer
Use the issuer chronology for the record. These focused indexes make it easier to compare the same official filing type across the monitored OTC universe.
PRIORITY FILING CUES
What to review next
Rules are applied to retained SEC filing types in this issuer record. They prioritize reading work; they are not ratings or conclusions.
- WATCHF-1/A2026-04-03 · form-type review cueSEC source →
- WATCHF-12026-03-16 · form-type review cueSEC source →
- CRITICALEFFECT2026-01-30 · form-type review cueSEC source →
- WATCHF-1/A2026-01-07 · form-type review cueSEC source →
- WATCHF-1/A2026-01-06 · form-type review cueSEC source →
Official filing timeline
- F-1/A · official filing
INNOCAN PHARMA Corp (INNP, INNPF)
- F-1/A · official filing
INNOCAN PHARMA Corp (INNP, INNPF)
- F-1/A · official filing
INNOCAN PHARMA Corp (INNP, INNPF)
- F-1/A · official filing
INNOCAN PHARMA Corp (INNP, INNPD)
- F-1/A · official filing
INNOCAN PHARMA Corp (INNP, INNPF)
- F-1/A · official filing
INNOCAN PHARMA Corp (INNP, INNPF)
INSTANT PUBLIC-RECORD FILE
Generate for this issuer · US$79 →Need a dated issuer evidence chain?
Generate a source-linked Shell Readiness File for first-pass internal screening. It organizes public records; it does not determine shell status or transaction feasibility.
EXTERNAL PUBLIC-RECORD CHECKS
Verify beyond this monitor.
These links open third-party official sources. They do not imply a match, a current quotation, a legal finding, or an OTC Markets data license.
COVERAGE STATUS
Request ticker review →What this dossier currently contains.
Issuer identityCurrent SEC OTC reference retainedLast directory observation: 2026-09-19
SEC record layer12 retained filing nodesLast stored capture: 2026-09-19 09:47
FINRA action layer0 matched actionsMatched by current ticker INNPF · last stored: Not retained
“Not retained” means this monitor does not currently hold a matching record in the named source layer. It does not establish absence, quotation status, compliance status, or issuer quality.
SEC FILING COMPLETENESS
Retained SEC record, including historical submissions.
Recent filings are retained from the SEC submissions index. On dossier visits, the monitor also checks the SEC’s older submission archive in the background. This is a filing-history view—not a quotation, trading, financing-close or capitalization record.
Historical archive check pending retry. 2026-09-19 11:29 UTC. “Not retained” or a low count means this monitor has not stored a matching filing; it does not establish absence of a filing or issuer activity.
SEC LITIGATION RELEASE CHECK
SEC Litigation Releases →Official release-title candidates, not a risk label.
The SEC describes Litigation Releases as records concerning civil actions brought by the Commission in federal court. This monitor checks only the SEC’s official release feed and only surfaces a strict company-name title candidate for human review.
No exact normalized company-name candidate in the retained SEC Litigation Releases cache. Feed cache: 2026-09-19 07:15 UTC.
A candidate does not confirm that this issuer is a respondent, defendant, affiliate, currently subject to an action, or associated with a filing. Names can overlap or change. Open the official SEC source and independently verify legal identity, entity status and context.
SEC NAME HISTORY
Names retained under this CIK.
These names come from the SEC submissions record and are useful identity clues when reviewing older filings or release titles. They do not independently prove a merger, reverse merger, ticker change, transaction date or continuity of business.
- INNOCAN PHARMA CorpCurrent SEC submission name
SEC STRUCTURED FINANCIAL FACTS
SEC Companyfacts JSON →Latest retained dollar facts, with period context.
Values come directly from SEC Companyfacts. Different facts can have different reporting periods or filing dates, so they are not combined into ratios or performance conclusions.
Source check: 2026-09-19 11:29 UTC. “Not retained” means no compatible USD fact was stored by this monitor; it does not establish that the company has no revenue, cash, assets, filings, operations or reporting obligation. Open the SEC filing for full context.
RESEARCH NOTES
Source-bound professional discussion.
Research Notes keep observations, questions and correction requests attached to the official-record workflow. This discussion layer is not a recommendation, valuation, legal conclusion or trading venue.
ISSUER COMMUNICATIONS
Open Newsroom Kit →Prepare a source-led update from this record.
Open the Newsroom Kit with this CIK already selected. It creates editable public-record drafts, a source citation and a review handoff—never a published release or a statement of issuer approval.
Company press releases
此区域仅收录公司新闻稿、公司公告或官网发布内容，不重复 SEC 申报动态。当前可先通过 OTC Markets 公司新闻页查看原文。
打开 OTC Markets 新闻原文 ↗Company press releases
公司新闻稿与公告将按公开来源归档；SEC 申报动态继续保留在原有 SEC 模块。
查看新闻稿入口 →Company press releases
Source available · Last updated: 2026/9/19 11:15:27
No press releases cached for this company.
View all press releases →